MedTrace Logo

Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)

NCT00941239 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-01-30

No results posted yet for this study

Summary

The purpose of this study is to determine the gastric tolerability and the pharmacokinetics of an extended release metformin compared with an immediate release metformin in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

metformin ER

850mg daily for 30 days

DRUG

metformin

850 mg daily for 30 days

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Oscar Torres, Ph D · UANL, Pharmacology and toxicology department

  • Jorge A Gonzalez · Laboratorios Silanes S.A. de C.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00941239 on ClinicalTrials.gov